Summary
Background
Parathyroid carcinoma as a cause of primary hyperparathyroidism is very rare. Clear consensus regarding the optimal management of patients with this condition is not available. We aimed to report our experience with this entity.
Methods
We analyzed medical records of patients who were operated for primary hyperparathyroidism and parathyroid carcinoma in the Centre for Endocrine Surgery in Belgrade, between January 2000 and December 2007.
Results
Seven patients (four men and three women) were operated for parathyroid carcinoma and primary HPT in our institution in this period. The age at initial diagnosis (mean ± SD) was 53.5 ± 7.6 years. All patients had hypercalcemia (mean 3.53 mmol/l) and very elevated parathyroid hormone (mean 1,530 pg/ml). Extirpation of the parathyroid tumor was performed in two patients, while in five patients parathyroidectomy was performed en block with all involved tissue. Average follow up was 47 months. One patient died for another disease, one was found to have increased calcium and parathyroid hormone levels postoperatively, while the remaining five were free of disease.
Conclusions
Surgery remains central in the management of patients with parathyroid carcinoma. Still, further multicentric studies should be performed for consistent treatment guidelines.
Similar content being viewed by others
References
Wynne AG, van Heerden J, Carney JA, Fitzpatrick LA. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore). 1992;71:197–205.
Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26:716–26.
Robert J, Trombetti A, Garcia A, Pache JC, Herrmann F, Spiliopoulos A, et al. Primary hyperparathyroidism: can parathyroid carcinoma be anticipated on clinical and biochemical grounds? Report of nine cases and review of the literature. Ann Surg Oncol. 2005;12:526–32.
Mittendorf EA, McHenry CR. Parathyroid carcinoma. J Surg Oncol. 2005;89:136–42.
Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86:485–93.
Ou HY, Hung WH, Hsu WH, Yu EH, Wu TJ. Variability of clinical presentations in three cases of parathyroid carcinoma. J Formos Med Assoc. 2003;102:266–69.
Hundahl S, Fleming I, Fremgen A, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995. Cancer. 1999;86:538–44.
Zivaljevic V, Krgovic K, Tatic S, Havelka M, Dimitrijevic Z, Diklic A, et al. Parathyroid cancer in a hemodialysis patient: a case report. Tumori. 2002;88:430–3.
Cavaco BM, Barros L, Pannett AA, Ruas L, Carvalheiro M, Ruas MM, et al. The hyperparathyroidism-jaw tumor syndrome in a Portuguese kindred. QJM. 2001;94:213–22.
Wassif WS, Moniz CF, Friedman E, Wong S, Weber G, Nordenskjold M, et al. Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab. 1993;77:1485–9.
Imanishi Y, Palanisamy N, Tahara H, Vickery A, Cryns VL, Gaz RD, et al. Molecular pathogenetic analysis of parathyroid carcinoma. J Bone Miner Res. 1999;14:405.
Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136:878–85.
Schantz A, Castleman B. Parathyroid carcinoma: a study of 70 cases. Cancer. 1973;31:600–5.
Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109(9):1736–41.
Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC, et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3803–8.
Miki H, Sumitomo M, Inoue H, Kita S, Monden Y. Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. Surgery. 1996;120:897–901.
Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg. 1991;15:738–44.
Shane E, Bilezikian J. Parathyroid carcinoma: a review of 62 patients. Endocr Rev. 1982;3:218–26.
Sandelin K, Auer G, Bondeson L, Grimelius L, Farnebo LO. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16:724–31.
Khan MW, Worcester EM, Straus FH 2nd, Khan S, Staszak V, Kaplan EL. Parathyroid carcinoma in secondary and tertiary hyperparathyroidism. J Am Coll Surg. 2004;199:312–9.
Holmes EC, Morton DL, Ketcham AS. Parathyroid carcinoma: a collective review. Ann Surg. 1969;169:631–40.
Ippolito G, Palazzo FF, Sebag F, De Micco C, Henry JF. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg. 2007;94(5):566–70.
Pelizzo MR, Piotto A, Beramasco A, Rubello D, Casara D. Parathyroid carcinoma. Therapeutic strategies derived from 20 years of experience. Minerva Endocrinol. 2001;26:23–9.
Sanchez SA, Iglesias AMA. Diagnostic-therapeutic management of parathyroid carcinoma. An Med Interna. 2002;9:644–8.
Chow E, Tsang RW, Brierley JD, Filice S. Parathyroid carcinoma—the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1998;41:569–72.
Conflict of interest
V. R. Zivaljevic, R. V. Zivic, A. Dj. Diklic, B. R. Bukvic, S. B. Tatic, M. R. Kazic, N. K. Kalezic, and I. R. Paunovic declare that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zivaljevic, V., Zivic, R., Diklic, A. et al. Parathyroid carcinoma in primary hyperparathyroidism: single institution experience. Eur Surg 44, 394–399 (2012). https://doi.org/10.1007/s10353-012-0180-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10353-012-0180-x